180+ chief medical officers to know | 2025

Image
hepatitis a vaccine :: Article Creator Hepatitis A Cases Reach A Three-year High, CDC Says By Lee I-chia / Staff reporter Cases of acute viral hepatitis A so far this year have reached a three-year high for local cases and an eight-year high for imported cases, with many of those who have been diagnosed with the disease being young people, the Centers for Disease Control (CDC) said yesterday. CDC Epidemic Intelligence Center Deputy Director Lee Chia-lin (李佳琳) said that as of Sunday, 56 local cases of acute viral hepatitis A had been reported so far this year. Most of those diagnosed were men at 76.8 percent, while the 30-to-39 age group had the largest case count at 46.4 percent of the total, followed by the 40-to-49 age group at 21.4 percent, Lee said. There have been 17 imported cases reported so far this year, she said. Cases of acute viral hepatitis A in previous years have typically numbered about 100, but there have bee...

John Theurer Cancer Center launches clinical trial of personalized cancer vaccine - NJBIZ

John Theurer Cancer Center at Hackensack University Medical Center said Friday that it is the only site in New Jersey, and one of just 17 in the country, participating in a multicenter international Phase II study of an innovative personalized cancer vaccine being evaluated in combination with pembrolizumab immunotherapy in patients with melanoma that has been surgically removed but has a high risk of coming back.

The expectation is that the vaccine can prime a patient’s immune system to be more responsive to immunotherapy and reduce the risk of cancer recurrence.

Utilizing a novel and potentially revolutionary gene-based technology, the vaccine is created by comparing the patient’s normal cell DNA sequence to that of their tumor and identifying tumor-specific changes to the DNA. Once identified, the patient-specific, tumor-specific changes are turned into a messenger RNA construct to be used as a vaccine.

Pembrolizumab belongs to a class of drugs called “checkpoint inhibitors,” which have transformed the treatment of melanoma. It works by blocking a protein called PD-1 which normally shuts down the immune response. Cancer cells use PD-1 to hide from the immune system. Inhibiting PD-1 enables the immune system to find and kill cancer cells.

“Pembrolizumab and other checkpoint inhibitors have been shown to reduce disease recurrence among patients with high-risk melanoma that was surgically removed. However, in many patients, the cancer eventually comes back,” said Dr. Andrew Pecora, a nationally recognized hematologist/oncologist at John Theurer Cancer Center and associate dean, Technology and Innovation, Hackensack Meridian School of Medicine at Seton Hall University, who is a principal investigator (PI) of the study.

“Reducing the rate of relapse would address a significant unmet medical need for these patients,” Pecora said.



Comments

Popular posts from this blog

These Are the Top Doctors in the Hudson Valley in 2022

William Buoni, MD - Wexner Medical Center

Who are the top doctors in Columbus? Search by specialty with Columbus Monthly's 2021 list